NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
企業コードNEO
会社名Neogenomics Inc
上場日Dec 10, 2012
最高経営責任者「CEO」Mr. Antony P. Zook
従業員数2200
証券種類Ordinary Share
決算期末Dec 10
本社所在地9490 Neogenomics Way
都市FORT MYERS
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号33912
電話番号12397680600
ウェブサイトhttps://neogenomics.com/
企業コードNEO
上場日Dec 10, 2012
最高経営責任者「CEO」Mr. Antony P. Zook
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし